top of page
  • Active, not recruiting

NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)

Updated: Sep 27, 2022

ELOQUENT-3 trial

NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Eloquent 3 myeloma trial

The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.


Sponsor


Collaborators

Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02654132

Official Title: An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

First Posted : January 13, 2016

Click here for details on ClinicalTrials.gov

 

 

Drug: Elotuzumab

Drug: Pomalidomide

Drug: Dexamethasone

 

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

N Engl J Med;2018

 

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

J Clin Oncol;2022 Aug

 

Location

United States, Georgia

United States, Illinois

United States, Indiana

United States, Massachusetts

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, South Carolina

United States, Tennessee

United States, Utah

United States, Washington

Australia, Queensland

Canada, Ontario

Canada, Quebec

Europe

France

Germany

Greece

Italy

Japan

Netherlands

Poland

Spain



Posts Archive
bottom of page